XH-02 Injection for Low Parathyroid Hormone Levels
Part of Hormones & metabolism clinical trials.
This study tests whether a new injectable medicine called XH-02 can safely treat hypoparathyroidism—a condition where your body doesn't make enough parathyroid hormone, causing low calcium levels. If your calcium isn't well-controlled with current treatments (calcium and vitamin D supplements), this trial might help.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Age 18–65 years old
- Diagnosed with chronic low parathyroid hormone (hypoparathyroidism) for at least 6 months
- Your calcium and parathyroid hormone levels aren't well-controlled by standard calcium and vitamin D treatment, or you can't tolerate those treatments
- Body Mass Index (BMI) between 17 and 40
- If under 26 years old, wrist X-rays must show your growth plates have closed
- No other serious kidney, liver, heart, or blood disorders that affect calcium metabolism
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new drug called XH-02 for hypoparathyroidism—a condition where your body doesn't make enough parathyroid hormone, causing low calcium levels. If you haven't improved with standard calcium and vitamin D treatments, this trial may help.
This trial tests an investigational drug called XH02 for people with hypoparathyroidism (low parathyroid hormone) that is not well controlled with standard calcium and vitamin D treatments. The goal is to see if XH02 is safe and effective at managing symptoms.
This study tests a new medicine called palopegteriparatide for teenagers with long-term hypoparathyroidism (low parathyroid hormone). The medicine is given as a daily injection and aims to help control calcium levels.
This trial is for adults with hypoparathyroidism who are already taking a drug called palopegteriparatide (TransCon PTH) at a certain dose. It tests whether higher doses of this drug can better control calcium levels and reduce the need for other supplements.
This trial tests an experimental drug called Canvuparatide against a placebo to see if it can help adults with a condition called hypoparathyroidism, where the body doesn't make enough parathyroid hormone. The goal is to improve calcium levels and reduce the need for high-dose calcium and vitamin D supplements.
This trial tests whether a donated parathyroid gland can help people with low parathyroid hormone (hypoparathyroidism) control their calcium levels and reduce symptoms. Participants will receive transplant and short-term immune-suppressing drugs.
Hear when a new Hypoparathyroidism trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.